JL
Therapeutic Areas
Deciphera Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| QINLOCK (Ripretinib) | Advanced GIST after 3+ TKIs | Approved |
| ROMVIMZA (Vimseltinib) | Symptomatic TGCT, not amenable to surgery | Approved |
| Tirabrutinib (ONO-4059) | Primary CNS Lymphoma (PCNSL), R/R | Phase 3 |
| Sapablursen | Polycythemia Vera, phlebotomy dependent | Phase 3 |
| ONO-4578 | Colorectal Cancer + nivolumab + chemotherapy | Phase 2 |
| Inlexisertib | Advanced GIST + ripretinib | Phase 2 |
| DCC-3009 | Advanced GIST | Phase 1 |
| DCC-2812 | Advanced/Metastatic Genitourinary Cancers | Phase 1 |